基于TCP的早期退缩指数预测直肠癌新辅助放化疗后的病理缓解
研究纳入74例接受新辅助放化疗(含奥沙利铂)的直肠腺癌患者,采用螺旋断层放疗并自适应方案(41.4 Gy/18次,2.3 Gy/次,最后6次对残留肿瘤同步整合加量至45.6 Gy),基于治疗前和治疗中T2加权MRI肿瘤体积构建早期退缩指数ERITCP,在65例可评估患者中评估其预测病理缓解的辨别力。结果显示ERITCP对pCR或cCR及RVC>10%的AUC分别为0.81和0.75(p<0.0005),敏感度86-89%,阴性预测值90-94%。
要点
- ERITCP对pCR或cCR的AUC为0.81,对RVC>10%的AUC为0.75(p<0.0005)。
- ERITCP敏感度86-89%,阴性预测值90-94%。
- 由熟练放射科医生勾画肿瘤体积的44/65例亚组中,ERITCP辨别力得到确认。
核心结论
- 基于早期退缩的放射生物学一致指数在新辅助放化疗后直肠癌病理缓解预测中表现出高性能,对自适应放疗/治疗定制具有相关潜力。
研究设计与样本
- 研究纳入74例接受含奥沙利铂新辅助放化疗的直肠腺癌患者,采用螺旋断层放疗并遵循自适应方案(41.4 Gy/18次,2.3 Gy/次,最后6次对残留肿瘤同步整合加量至45.6 Gy),于治疗前和治疗中行T2加权MRI并考虑相应肿瘤体积(Vpre、Vmid)。
主要发现
- 65例患者数据完整,其中pCR 20例、cCR 2例、RVC>10% 19例。
- ERITCP对pCR或cCR的AUC为0.81,对RVC>10%的AUC为0.75(p<0.0005)。
- ERITCP敏感度为86-89%,阴性预测值为90-94%。
- 在由熟练放射科医生勾画肿瘤体积的44/65例亚组中,ERITCP的辨别力得到确认。
关键数值与推荐
- ERITCP对pCR或cCR的AUC=0.81,对RVC>10%的AUC=0.75(p<0.0005)。
- ERITCP敏感度86-89%,阴性预测值90-94%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Introducing a radiobiological index based on early tumor regression during neo-adjuvant radio-chemotherapy (RCT, including oxaliplatin) of rectal adenocarcinoma and testing its discriminative power in predicting the tumor response. METHODS: Seventy-four patients were treated with Helical Tomotherapy following an adaptive (ART) protocol (41.4 Gy/18 fr, 2.3 Gy/fr) delivering a simultaneous integrated boost on the residual tumor in the last 6 fractions up to 45.6 Gy. T2-weighted MRI were taken before (MRIpre) and at mid (MRImid) therapy and the corresponding tumor volumes were considered (Vpre,Vmid). The "Early Regression Index" [Formula: see text] was introduced and its discriminative power was assessed in terms of AUC, sensitivity/specificity, positive/negative predictive value (PPV/NPV). Two end-points were considered: (a) pathological complete response (pCR) or clinical complete response followed by watch-and-wait, (cCR); (b) limited response (residual vital cells (RVC) in the surgical specimen >10%). RESULTS: Complete data were available for 65 patients: pCR, cCR and RVC >10% were 20, 2 and 19 respectively. The discriminative power of ERITCP was moderately high (AUC = 0.81/0.75 for /pCRorcCR/RVC >10% respectively, p < 0.0005). ERITCP was highly sensitive (86-89%) with very high NPV (90-94%). The discriminative power of ERITCP was confirmed on a subgroup of 44/65 patients when considering tumor volumes delineated by a skilled radiologist. CONCLUSION: A radiobiologically consistent index based on early regression showed high performances in predicting the pathological response after neo-adjuvant RCT for rectal cancer with relevant potentialities for ART/treatment customization.
引用
- Fiorino C, Gumina C, Passoni P, et al. A TCP-based early regression index predicts the pathological response in neo-adjuvant radio-chemotherapy of rectal cancer. Radiother Oncol. 2018. PMID: 30196982. doi:10.1016/j.radonc.2018.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。